On April 30, 2015, the pCODR Expert Review Committee (pERC) issued initial recommendations for Romi
Jun 01 2015
Burkitt’s lymphoma (BL) is a type of non-Hodgkin lymphoma. It is characterized by a mutation in a gene called myc, which triggers the BL cells to grow uncontrollably. However, much is still unknown about the cause of the disease.
May 27 2015
Managing the Side Effects of Chemotherapy
May 21 2015
This award recognizes a CANO/ACIO member whose actions support the concept of patient advocacy and decision making, or who promotes change within the oncology/hematology communities.
May 01 2015
Apr 08 2015
Health Canada approves ZYDELIG™ (idelalisib) for treatment of relapsed chronic lymphocyctic leukemia and conditionally approves ZYDELIG™ for follicular lymphoma.
Apr 02 2015
Lymphoma Canada has created a personalized portal with resources tailored to the off-treatment phases of your lymphoma experience.
Mar 30 2015
The CanCertainty Coalition, a collaboration of 35 cancer patient groups, physicians and national healthcare charities founded one year ago to challenge inequities in cancer care and treatment, applauds Cancer Care Ontario (CCO)’s recent Report
Mar 17 2015
Lymphoma Canada is conducting a survey of CLL patients with experience with idelalisib (Zydelig) to appeal to Canadian governments to provide funding for this treatment in Canada.
Feb 18 2015
Applications are now being accepted for the Lymphoma Canada Research Fellowship award.